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Abstract Methotrexate (MTX), the primary treatment for
the articular-type juvenile idiopathic arthritis (JIA), is
effective and brings about radiological improvement.
Patient compliance is good, and it is recognized that its
known side effects, namely, disruption of liver function and
induction of pulmonary lesions, are unlikely to be severe at
the low MTX doses that are administered. In Japan, MTX
was granted approval in 1999 by the then Ministry of Health
and Welfare speciﬁcally for treating rheumatoid arthritis in
adult patients, allowing it be generally used in medical
institutions for patients having National Health Insurance.
However, in the pediatric ﬁeld, its use outside the indica-
tions has so far been unavoidable, and has been left to
the discretion of the physician. Finally, at the present
conference, expansion of the indications of MTX for JIA
was approved in Japan. It is noteworthy that this expansion
of indications was achieved without requiring clinical trials
on children sponsored by the pharmaceutical company: it
was achieved rather by collecting necessary information
through ongoing efforts (including collection and analysis
of information about approval status in foreign countries,
adequate evidence from the literature, implementation of a
clinical use survey in Japan, etc.). It also merits attention
that the maximum dose (10 mg/m
2) was set on the basis of
pharmacokinetic data from children, rather than relying on
the dosing method and dose for adults.
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Introduction
It has already been demonstrated in randomized, controlled
trials that methotrexate (MTX), the treatment of choice for
articular-type juvenile idiopathic arthritis (JIA), which is
also called ‘‘juvenile rheumatoid arthritis (JRA)’’, is more
effective than a placebo and brings about radiological
improvement. Patient compliance is good. Furthermore,
side effects, namely, disruption of liver function and
induction of pulmonary lesions, are unlikely to be severe at
the low MTX doses that are administered.
Outside Japan—for instance, in the United States and in
the European Union—it has already been approved for the
treatment of chronic arthritis. In Japan also, it was granted
approval in 1999 by the then Ministry of Health and
Welfare speciﬁcally for treating rheumatoid arthritis (RA)
in adult patients, and could then generally be used in
medical institutions for patients having National Health
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DOI 10.1007/s10165-008-0123-3Insurance. As a result, it has proved useful for reducing
symptoms in many patients with swollen and painful joints
and for inhibiting the progression of arthritis. However, in
the pediatric ﬁeld, its use outside the indications has so far
been unavoidable, and has been left to the discretion of the
physician.
In the present study, in addition to fulﬁlling the condi-
tions for obtaining approval overseas, we expanded the
range of indications by collecting large amounts of evi-
dence from the literature and by surveying the conditions
of use in Japan without conducting pediatric clinical trials;
moreover, we were able to set the maximum child dose on
the basis of the pharmacokinetics in children without being
restricted to the method and dosage of administration in
adult RA. As for this report, the contents were examined
closely in the working group of MTX for JIA, and dis-
cussion was accomplished in the study group on pediatric
drug therapy in Ministry of Health, Labour and Welfare.
Finally, this expansion of the indications was approved
after prior evaluation by Pharmaceutical Affair / the ﬁrst
Food Sanitation Investigation Council Medical Supplies
Sectional Meeting, and the application was completed by a
notice of examination management chief in the Medicine
Food Station on 30 March 2008.
Present status of MTX therapy for JIA in Japan
Juvenile idiopathic arthritis is a chronic systemic inﬂam-
matory disease developing during childhood [1, 2].
According to a nationwide survey in Japan, this disease
develops in about one out of 100,000 children per year, with
a prevalence of 9.74 of 100,000 children less than 16 years
of age [3, 4]. Major symptoms include articular swelling
and pain associated with persistent inﬂammation. Tissue
destruction and ﬁbrosis tend to accumulate over time in
patients with this condition. Unless treated appropriately,
patients with this disease are likely to suffer deformation
and contracture of joints due to articular collapse as well as
osseous rigidity of joints affected by advanced JIA, leading
to severe dysfunction. When this disease develops at an
early age, there is a risk of growth retardation.
At present, non-steroidal anti-inﬂammatory drugs
(NSAIDs) are used to treat inﬂammation in the early stages
JIA [5]. In the USA, three drugs (aspirin, naproxen, tol-
metin) have been approved for use in the treatment of JIA.
Ibuprofen is also used in the USA (‘‘off-label’’) for the
treatment of JIA, since the dose of this drug for children is
given in the package insert. In Japan, however, no NSAIDs
have been approved for use in JIA treatment, and ibuprofen
is used only for pain control. Thus, the drugs available in
Japan for children with this disease are quite limited, and
only steroids are indicated for JIA.
Extensive clinical studies on MTX in children with
arthritis began to be carried out in the 1980s, primarily in
Western countries. Adverse reactions were minimal, and
the drug was reported to begin suppressing arthritis several
weeks after the start of treatment in children with JIA who
had only responded to steroids previously [6–8]. In ran-
domized comparative studies as well, MTX was shown to
be more effective than the placebo and to produce radio-
logical improvement when used in cases with multiple-
joint involvement. Based on these results, this drug was
approved in the USA as a means of treating JIA [9]. In the
EU, the approval status of MTX varies among different
member countries, but sick children have been enjoying
major beneﬁts from this drug [10, 11]. In Japan, on the
other hand, even the MTX 2 mg preparation, approved as a
drug speciﬁcally indicated for rheumatoid arthritis, has a
precaution in its package insert stating that the safety of
this preparation in children and so on has not been estab-
lished (experience in children and other special cases is
poor). Thus, the use of MTX for the treatment of JIA has
not been ofﬁcially authorized in Japan [12]. Under such
circumstances, treatment with conventional steroids and
NSAIDs has been continued at many of the facilities where
clinicians not specializing in JIA care manage JIA patients.
At facilities specializing in JIA, MTX has been used as a
drug of ﬁrst choice, but, since the MTX 2 mg preparation
used for treatment of JIA is not covered by national health
insurance, a cheaper MTX 2.5 mg preparation (ofﬁcially
approved for use in the treatment of malignant tumors) has
also been used in addition to the MTX 2 mg preparation.
Furthermore, since the MTX 2 mg preparation is not
authorized for use in the treatment of JIA and because the
MTX 2.5 mg preparation has been authorized solely for
treating malignant tumors in Japan, severe adverse reac-
tions to MTX which appear following the use of this drug
for treating JIA (even when used appropriately), patients
may not be entitled to compensation system (Relief System
for Sufferers from Adverse Drug Reactions).
The Association of Children with JIA and Their Parents
has been insisting on correction of inter-regional differ-
ences in opportunities to receive JIA treatment, pointing
out facilities with JIA specialists are conﬁned to particular
regions, and that JIA patients have difﬁculty receiving
MTX therapy at non-specializing facilities, resulting in a
marked inter-regional difference in the disease remission
rate. If MTX is approved for use in the treatment of JIA
and if an appropriate dosage, administration method, etc.
are established concerning for this therapy, children with
JIA across Japan can enjoy beneﬁts equally, and signiﬁcant
impacts are expected in clinical practice related to JIA
management. In fact, the cases necessitating treatment of
sequelae secondary to JIA have been decreasing since
adoption of MTX therapy at facilities specializing in JIA,
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MTX will also be useful in reducing the cost of some care
which is unnecessary in those treated with MTX.
Another factor making this an urgent issue is that bio-
logical preparations indicated for JIA have already been
approved in Western countries and have been clinically
reported to alleviate arthritis more markedly than is
expected of MTX. In Japan, clinical trials on some of these
biological preparations have been completed and approvals
for these preparations have been or will be issued. New
evidence has shown that combined use of MTX is indis-
pensable for maximizing the effects of these biological
preparations, particularly their effects on articular collapse
[13–15]. A problem with these drugs is their high cost. This
problem was also highlighted in Western countries, but
these drugs were eventually approved on the basis of the
medico-economic view that the total cost could be reduced
by the use of these drugs if the cost-to-beneﬁt relationship
in patients’ social contributions and the impacts on other
healthcare costs, etc. were taken into account. In Western
countries, the use of these biological preparations is limited
to cases in which adequate efﬁcacy cannot be expected of
existing treatments. If these biological preparations are
clinically introduced in Japan before approval of MTX as
a JIA treatment, physicians in Japan will tend to use
these preparations excessively, without adequate care,
possibly exerting profound impacts on overall healthcare
expenditures.
Status of approval in four Western countries (USA, UK,
Germany and France)
MTX in JIA is approved in USA, Germany and France as
indicated by Tables 1, 2. Additionally, in UK, although
only adult RA has been established, guidance on the use of
a biological preparation (etanercept) for JIA treatment,
prepared by the National Institute for Clinical Excellence
(NICE), shows the indication.
Overseas published information, randomized
comparative studies and reports on pharmacokinetics
Overseas literature search results
The related literature was sought via Pub Med (http://
www.ncbi.nlm.nih.gov/entrez/query.fcgi) (1950–2006), a
Table 1 The status of approval in the Western countries
Country Indications Dosage and administration
USA Rheumatoid arthritis including multiple-
joint juvenile rheumatoid arthritis
The recommended initial dose is 10 mg/m
2 (once weekly). The
dose is changed gradually until adequate efﬁcacy can be
achieved. In adults, the incidence of severe adverse reactions
(particularly marrow suppression) rises signiﬁcantly if the dose
exceeds 20 mg/week. For children, the maximum reported dose
is 30 mg/m
2 per week. However, adequate safety evaluations
have not been conducted at doses over 20 mg/m
2 per week.
Usually, efﬁcacy appears within 3–6 weeks, and efﬁcacy
augmentation lasts for at least 12 weeks. Although the duration
of action has not been deﬁnitely documented, reports on the use
of this drug in adults demonstrated that even when initial
clinical efﬁcacy was not sufﬁciently high, efﬁcacy persisted
during a 2-year treatment period. If the drug is discontinued,
exacerbation of arthritis usually appears within 3–6 weeks
UK Adult RA only (except for use of this drug
in treating cancer, neither the efﬁcacy
nor the safety of the drug in children)
has been established
a
When used for adults with RA, the initial dose is 7.5 mg (once
weekly or three 2.5 mg doses at intervals of 12 h/week). The
dose may be increased to 15–20 mg (25 mg at maximum) per
week. According to the NICE guidance on the use of biological
preparations for JIA treatment, MTX is used as a standard drug,
and is administered via non-oral routes at a dose of 20 mg/m
2
per week (maximum non-toxic dose) for 3 months
Germany Multiple-joint juvenile idiopathic arthritis
(JIA at age over 3 years)
Dosage and administration: Recommended dose is 10–15 mg/m
2
per week. If adequate efﬁcacy is not obtained, a higher dose
(20–30 mg/m
2 per week) is permitted.
France Juvenile idiopathic arthritis Recommended initial dose is 10 mg/m
2. Can be increased to
20 mg/m
2 at maximum
a Guidance on the use of a biological preparation (etanercept) for JIA treatment, prepared by the National Institute for Clinical Excellence
(NICE), includes the statement: ‘‘Although MTX is generally used as a DMARDs for the treatment of JIA, the use of DMARDs including MTX
has not been approved in the UK. However, the biological preparation is used in cases where MTX is not effective’’
Mod Rheumatol (2009) 19:1–11 3
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National Institutes of Health (NIH), USA, and the EM-
BASE (1974–2006) operated by Elsevier Science B.V., the
Netherlands. Among the numerous reports contained in
these databases, our search and quotation focused on
papers related to expansion of the indications for MTX in
JIA (primarily those cited by the Cochran Review).
Double-blind randomized comparison of MTX
with placebo
A double-blind study was carried out, dividing 127 patients
with JIA younger than 18 years and satisfying the ACR
criteria (mean age: 10.1 years, mean duration of sickness:
5.1 years) into the following three groups and administering
MTX or placebo once weekly for 6 months: Group A (46
patients treated once weekly with MTX 10 mg/m
2; dose
increased to 15 mg/week at maximum), Group B (40
patients treated once weekly with MTX 5 mg/m
2) and
Group C (41 patients treated with a placebo) [9]. Con-
comitant use of prednisone (10 mg/day or less) and two
non-steroidal anti-inﬂammatory drugs was permitted. The
percentage of concomitant prednisone users was 33%
(15 cases) in Group A, 37% (15 cases) in Group B and 34%
(14 cases) in group C. Efﬁcacy and safety were evaluated in
accordance with the Guidelines prepared by the Pediatric
Rheumatology Collaborative Study Group [16]. Efﬁcacy
was evaluated in 114 cases, with the response rate (per-
centage of cases showing improvement) being signiﬁcantly
higher in Group A (63%) than in Group B (32%) or Group C
(36%) (P = 0.013). Group A showed a signiﬁcantly greater
reduction from the baseline as compared to Group C in
terms of the number of painful joints during exercise (-11.0
vs. -7.1), pain severity score (-19.0 vs. -11.5), number of
joints with restricted range of motion (-5.4 vs. -0.7) and
erythrocyte sedimentation rate (-19.0 vs. -6.0 mm/h).
Side effects (SEs) were noted in 6 cases (13%) from Group
A, 8 (20%) from group B and 5 (12%) from Group C. Major
SEs observed were gastrointestinal disorders, stomatitis,
headache, abdominal pain and dizziness, none of which was
severe. Treatment was discontinued because of SEs in two
cases from Group A (abnormal liver enzyme levels and
hematuria) and one case from Group B (eruption). All of
these SEs subsided rapidly after discontinuation of the drug.
The investigators stated that MTX therapy (10 mg/m
2 per
week) provides a valid means of treating therapy-resistant
JIA and that it is a safe therapy if administered for a short
period of time (6 months or less).
A multicenter placebo-controlled double-blind random-
ized crossover comparative study was carried out in 88
children with JIA younger than 16 years of age, including
43 children satisfying the criteria for erosive osteoarthritis
Table 2 Double-blind randomized study of MTX for JIA in the Western countries
Author Journal Comparison Summary
Giannini
et al. [9]
N Engl J Med.
1992
Placebo A total of 127 patients with JIA younger than 18 years and satisfying the ACR
criteria (mean age: 10.1 years, mean duration of sickness: 5.1 years) were
enrolled into the following three groups: Group A (46: once weekly with MTX
10 mg/m
2; dose increased to 15 mg/week at maximum), Group B (40: once
weekly with MTX 5 mg/m
2) and Group C (41: placebo). Efﬁcacy was evaluated
in 114 cases, with the response rate (percentage of cases showing improvement)
being signiﬁcantly higher in Group A (63%) than in Group B (32%) or Group C
(36%). Side effects (SEs) were noted in 6 cases (13%) from Group A, 8 (20%)
from group B and 5 (12%) from Group C. Major SEs observed were
gastrointestinal disorders, stomatitis, headache, abdominal pain and dizziness,
none of which was severe. The investigators stated that MTX therapy (10 mg/m
2/






Placebo A total of 88 children with JIA younger than 16 years of age were studied, including
43 children satisfying the criteria for erosive osteoarthritis (EOA) and 45
satisfying those for generalized arthritis. MTX or placebo was orally administered
once weekly at a dose of 15–20 mg/m
2 for the ﬁrst 4 months, followed by
4-month administration of placebo or MTX in an alternating fashion after a two-
month cessation. When the data from both disease groups were combined, MTX
therapy resulted in signiﬁcant clinical improvement (P = 0.006). Major SEs
observed were nausea, upper gastrointestinal disorders, stomatitis, dysthymic
disorder and elevated AST, but there were no signiﬁcant differences in SEs
between the MTX and placebo groups. Thus, this short-term study revealed that
oral MTX treatment (15–20 mg/m







Leﬂunomide A total of 94 patients with multiple-joint JIA (age: 3–17) were enrolled. The JIA
response rate was high for both leﬂunomide (LEF) and MTX, but MTX seemed to
be more effective against JIA than LEF at the doses studied
4 Mod Rheumatol (2009) 19:1–11
123(EOA) and 45 satisfying those for generalized arthritis
[10]. Forty-three patients with EOA and 45 with general-
ized arthritis were enrolled in the study. MTX or placebo
was orally administered once weekly at a dose of 15 mg/
m
2. The dose was gradually increased to 20 mg/m
2 during
the 2-month period. Either MTX or placebo was adminis-
tered for the ﬁrst 4 months, followed by 4-month
administration of placebo or MTX in an alternating fashion
after a 2-month cessation. In the EOA group, signiﬁcant
improvement was noted in 3 of 5 major parameters, i.e.,
erythrocyte sedimentation rate (ESR) and overall disease
activities assessed by the physician or by the parents. In
addition, signiﬁcant overall improvement was noted in the
EOA group according to the primary improvement criteria.
In the generalized arthritis group, signiﬁcant improvement
was noted in only two of the ﬁve parameters (overall dis-
ease activities assessed by the physician or by the parents,
with no signiﬁcant difference in systemic characteristic
scores between the MTX and the placebo treatment peri-
ods). However, in terms of therapeutic efﬁcacy, there was
no signiﬁcant difference between the EOA and systemic
arthritis groups. When the data from both disease groups
were combined, MTX therapy resulted in signiﬁcant clin-
ical improvement (P = 0.006). Major SEs observed were
nausea, upper gastrointestinal disorders, stomatitis, dys-
thymic disorder and elevated AST, but there were no
signiﬁcant differences in SEs between the MTX and pla-
cebo groups. Thus, this short-term study revealed that oral
MTX treatment (15–20 mg/m
2 once weekly) was effective
against EOA and systemic JIA. The investigators empha-
sized the necessity of examining the long-term efﬁcacy of
this drug in future studies.
Double-blind randomized studies comparing MTX
with other drugs
A multi-country, double-dummy randomized comparative
study was carried out on 94 patients with multiple-joint JIA
(age: 3–17). The JIA response rate was high for both le-
ﬂunomide (LEF) and MTX, but MTX seemed to be more
effective against JIA than LEF at the doses studied [17].
Other randomized comparative studies
Evaluation of the effects of MTX dose increase [18]
The 595 JIA patients, who began MTX therapy at a standard
dose (8–12.5 mg/m
2 per week, oral, subcutaneous or
intramuscular), were followed for 6 months. Of these
patients, 80 failed to show 30% improvement in ACR [19,
20], and were assigned at random to either the medium
MTX dose group (15–20 mg/m
2 per week, n = 40) or the
high MTX dose group (30–40 mg/m
2 per week, n = 40)
and received intramuscular or subcutaneous injections of
the drug for another 6 months. The results suggest that the
efﬁcacy of MTX against JIA plateaus at a dose of 15 mg/m
2
per week (non-oral) and that treatment needs to be contin-
ued for 9–12 months to evaluate the efﬁcacy of MTX.
Evaluation of the inﬂuence of concomitant use of folic acid
on the clinical efﬁcacy of MTX [21]
A randomized placebo-controlled double-blind 13-week
cross-over comparative study was carried out to evaluate
the inﬂuence of concomitant use of folic acid (1 mg/day)
on the efﬁcacy of MTX administered to control disease
activity in JIA patients. In these patients, concomitant
use of 1 mg of folic acid at the time of weekly oral
MTX treatment did not affect the clinical efﬁcacy of
MTX.
Literature dealing with in vivo drug kinetics
In vivo kinetics following an oral dose of MTX to children
The report made by Balis et al. suggests that when MTX is
orally administered in an amount exceeding a certain level,
saturation of its absorption needs to be taken into account
[22].WhenMTX(6.8–28.1 mg/m
2)wasorallyadministered
to children between 4 and 14 years of age (ALL: 14 cases,
dermatomyositis: one case), those receiving 12 mg/m
2 or
higher doses showed prolongation of the absorption phase
from 1.5 ± 0.6 h to 2.5 ± 1.1 h (P\0.05) and a reduction
intheabsorptionratefrom87to51%(P\0.05),suggesting
a mechanism for saturation of absorption.
Kinetics in patients with JIA
Ravelli et al. [23] analyzed plasma MTX levels following
oral administration of MTX (6.4–11.2 mg/m
2 per week) to
33 patients with severe JIA (ages: 1–19 years). The plasma
MTX level at 3 h after administration was higher in ‘‘the
MTX ? salicylic acid treatment group’’ than in ‘‘the
MTX ? other NSAID treatment group’’ (mean: 0.23 vs.
0.39 lM). There was no difference in the MTX dose or
plasma MTX level between responders (15 cases) and
nonresponders (seven cases) or between those with (15
cases) and without (seven cases) elevated serum transam-
inase levels. Albertioni et al. [24] analyzed the kinetics of
MTX and its metabolite 7-OHMTX following a single oral
dose of MTX (0.14–0.24 mg/kg; median = 0.21 mg/kg) to
13 patients with JIA (ages: 5–16 years). Larger amounts of
MTX are reportedly needed to treat pediatric JIA than adult
RA since the AUC of MTX is lower in children. The age-
related changes in MTX kinetics revealed by these studies
may explain this ﬁnding.
Mod Rheumatol (2009) 19:1–11 5
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Dupuis et al. [25] evaluated the effects of NSAIDs with
recognized MTX interactions. They analyzed changes in
MTX kinetics following a single MTX dose (5–8.9 mg/m
2
per week, oral) or of MTX in combination with one or more
NSAIDs (tolmetin, indomethacin, naproxen and aspirin) in
seven children with chronic arthritis (ages: 8–18 years). In
six of these seven cases, multiple NSAIDs were adminis-
tered. Following combined MTX ? NSAID treatment, the
mean half-life of MTX was signiﬁcantly prolonged
(1.7 ± 0.5 vs. 1.2 ± 0.1/h, P = 0.03). However, no sig-
niﬁcant change was noted in MTX clearance (10.6 ± 5.5
vs. 13.1 ± 3.5 L/h, P = 0.19), AUC (2.1 ± 1.0 lmol/L
per h vs. 1.5 ± 0.6 lmol/L per h, P = 0.08) or distribution
volume (Vd; 23 ± 6.2 vs. 21.9 ± 6.4 L, P = 0.53). Based
on these results, the investigators pointed out the necessity
of considering MTX dose reduction when the NSAID dose
is increased or additional NSAIDs are used.
Inﬂuence of diet
Because diet was shown to inﬂuence MTX therapy in some
children, administration of this drug in a fasted state has
been recommended. Pinkerton et al. [26] analyzed the
inﬂuence of diet on absorption of orally administered MTX
(15 mg/m
2) in ten children with acute lymphoblastic leu-
kemia (ages: 3–15 years). Each child received three doses
of MTX. The drug was ﬁrst administered in a fasted state
(A), then with a milk-dominant meal (B) and ﬁnally during
an orange-dominant meal (C). Mean Cmax were 0.91, 0.55
and 0.71 lM following doses A, B and C, respectively.
Mean Tmax were 1.30, 2.15 and 1.88 h, mean AUC 2.18,
1.56 and 1.91 lM/h per L following doses A, B and C,
respectively. Thus, administration of MTX with a milk-
dominant meal resulted in a signiﬁcantly lower blood MTX
level (P\0.05), and absorption of MTX was delayed by
its intake with either of the two meal types. The AUC
during the absorption phase of the drug was signiﬁcantly
lower in the milk-dominant meal group than in the ‘empty
stomach’ group (P\0.05). Dupuis et al. [27] administered
MTX to 14 patients (ages: 2.8–15.1 years, including 10
females) for 3 weeks using three dosing methods (admin-
istration after a meal, administration after overnight
hunger, and intravenous administration). They compared
the data from 13 patients for whom evaluation was possi-
ble. Blood was sampled 0, 0.5, 1, 1.5, 2, 3, 4 and 6 h after
oral treatment, 0, 0.08, 0.25, 0.5, 1, 1.5, 2, 3, 4 and 6 h after
intravenous treatment. The mean excretion rate constants
were 0.27 ± 0.065, 0.26 ± 0.067 and 0.25 ± 0.11/h for
the post-meal, ‘empty stomach’ and intravenous groups,
respectively. The corresponding AUC were 1.87 ± 0.83,
1.50 ± 0.51 and 1.85 ± 0.80 lmol/L h. Thus, there were
no inter-group differences in excretion rate constant or
AUC. Peak blood drug concentration (Cmax) was signiﬁ-
cantly lower in the post-meal group (0.39 ± 0.18 lmol/L)
than in the ‘empty stomach’ group (0.65 ± 0.33 lmol/L)
(P = 0.0022). The time until peak blood drug concentra-
tion also differed between the ‘empty stomach’ group
(0.94 ± 0.41 h) and the post-meal group (1.32 ± 0.68 h)
(P = 0.1464). As a result, bioavailability was higher in the
‘empty stomach’ group (1.1 ± 0.51) than in the post-meal
group (0.88 ± 0.35) (P = 0.0211).
Clinical pharmacodynamic studies
Bannwarth et al. [28] reported their clinical pharmacody-
namic analysis of MTX following intermittent low-dose
administration, using immunoassay. Following a low oral
dose of MTX (B10 mg/m
2), the absorption rate averaged
70% both following a post-meal dose and a dose given on
an ‘empty stomach’. The mean serum albumin binding rate
of MTX was 42–57%. They reported that there was no
evident relationship of pharmacodynamic parameters to
clinical efﬁcacy or toxicity of MTX in patients with
rheumatoid arthritis. They additionally stated that when
using MTX for children, it should be taken into account
that pharmacokinetics vary depending on age.
Relationship between blood MTX level and toxicity
Wallace et al. [29] reported on the relationship between the
blood MTX level and toxicity. They orally administered
MTX (0.11–0.6 mg/kg per week) for 1.6 years (median) to
23 patients with JIA (age: 4.3–18.8 years) and attempted to
determine safe and effective doses of MTX through anal-
ysis of blood drug levels in relation to clinical ﬁndings.
MTX was used in combination with NSAIDs (ibuprofen,
indomethacin, naproxen, piroxicam, salicylic acid, sulindac
or tolmetin), sulfasalazine, hydroxychloroquine or PDN. In
seven cases, serum transaminase levels rose slightly. In
three of these seven cases, medication was temporarily
suspended. In the other four cases, the abnormality sub-
sided without requiring dose discontinuation or reduction.
For the former three cases, medication was resumed at a
lower dose after enzyme level normalization, and no
problems were noted thereafter. The blood MTX level was
not affected by concomitant use of any other drugs. In 21
cases, symptoms were signiﬁcantly alleviated. The inves-
tigators concluded that safe MTX doses would be 0.6 mg/
kg per week or less.
Other comparative studies
The inﬂuence of vaccination was evaluated in individuals
receiving hepatitis B immunizations [30]. Thirty-nine
6 Mod Rheumatol (2009) 19:1–11
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face antigen (HbsAg) negative and 41 healthy children
were compared. The children with JIA showed adequate
responses to hepatitis B vaccination, showing no effects of
the immunosuppressant administered. The data suggested
administering the drug 0, 1 and 6 months after vaccination
to be more favorable to than administering it 0, 1 and
3 months after vaccination.
Reviews of peer-reviewed journals, reports
on meta-analyses
Cochran Review [31] involved a search and review of
randomized comparative studies using the Cochran Con-
trolled Trials Register (CCTR) and MEDLINE. The
criterion used for selection was randomized comparative
studies or clinical comparative studies, involving compar-
ison of MTX therapy with placebo or standard care in
patients with JIA. A systematic review was conducted on
the effects of MTX therapy on mechanical capabilities,
range of motion, quality of life, overall satisfaction and
pain in JIA patients. Two studies on JIA patients [9, 10]
were reviewed. The review revealed that MTX therapy
resulted in greater improvement as compared to placebo
treatment in terms of range of joint motion, number of
painful joints, number of swollen joints, assessments by the
physician and by the parents, allowing the conclusion that
treatment with MTX can alleviate disorders to a degree
equivalent to or higher than the minimal clinically signif-
icant level ([20%).
Giannini et al. [32] conducted a meta-analysis of the
efﬁcacy and safety of MTX administered at two low doses
[5MTX (5 mg/m
2 per week), 10MTX (10 mg/mg
2 per
week)] in comparison to D-penicillamine (10 mg/kg per
day), hydroxychloroquine (6 mg/kg per day) and auranoﬁn
(0.15–0.20 mg/kg per day) in 520 JIA patients enrolled in
three randomized placebo-controlled studies. Their analy-
sis revealed that only 10MTX resulted in marked
improvement as compared to the placebo treatment in
terms of overall assessment by physicians, overall index
and erythrocyte sedimentation rate. Responses to treatment
were highest in the 10MTX group in evaluation of all
joints. Short-term safety did not differ between any two
groups. The results suggested that low-dose MTX would be
useful as the ﬁrst-line drug therapy for JIA. It was con-
cluded that the minimum effective dose of MTX is 10 mg/
m
2 per week.
The review by Ravelli et al. [33] on MTX therapy for
JIA discussed the dose, route of administration, toxicity,
timing of treatment start, timing of discontinuation of the
drug, differences in the efﬁcacy of MTX for JIA depending
on the time of disease onset, capability of the drug to
modify the course of JIA, and the signiﬁcance of using
MTX in combination with second-line drugs. To brieﬂy
summarize the discussions in this review, MTX is an
effective, well-tolerated and low-cost drug for JIA treat-
ment. Although the investigators did not refer to the
possibility that MTX could alter the long-term prognosis of
JIA patients, they stated that the drug markedly altered the
short-term and mid-term outcomes in many sick children.
Recent studies of adult RA yielded results supporting the
use of MTX in combination with etanercept and inﬂiximab
(new anti-tumor necrosis factor preparations).
MTX in the guidelines for JIA management prepared
by academic societies or organizations
A guide to treatment of JIA (JRA) using MTX was pub-
lished in August 2007 by the Pediatric Rheumatology
Association of Japan, under the title ‘‘Guide to Initial
Management of Juvenile Idiopathic Arthritis (2007)’’ [34].
Currently, in parallel with the discussions at this confer-
ence, a revised version is now being prepared to provide
more detailed statements to ensure proper use of MTX.
Among overseas guidelines, use of etanercept for JIA
treatment was recently published by the NICE [11] and
refers to the role of MTX in JIA treatment as follows:
Treatment of JIA uses NSAIDs and DMARDs. MTX is
a major DMARD for treating this disease. Since MTX is
expected to be effective in about 85% of multiple-joint
type JIA cases, it is used as the ﬁrst-line drug. For patients
not responding to at least 3 months of MTX therapy at a
dose of 20 mg/m
2 per week (the maximum dose inducing
no marked adverse reaction), etanercept (a biological
preparation) should be selected.
Use of MTX for JIA patients in Japan
According to the questionnaire survey conducted in 2000 at
eight facilities in Japan, specializing in pediatric rheuma-
tology (70 subjects, 19 males and 51 females), the mean
age at disease onset was 6.9 years, mean duration of
sickness 8.2 years and mean age at start of MTX therapy
13.2 years. The survey revealed approximately 73% of
cases showed disease remission in response to combined
MTX therapy. The duration of MTX therapy was 1–3 years
in 25% and over 3 years in 61% of all cases, indicating that
about 80% of all cases were able to take this drug for
prolonged periods of time [35].
In the clinical use survey conducted to prepare this par-
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2 and an average of
8.73 ± 3.72 mg/m
2. The absolute MTX dose was 2 mg/
week at minimum, 20 mg/week at a maximum, with a
median of 7.5 mg/week as, and average of 8.37 ± 3.70 mg/
week. Thus, the amount of MTX used was greater than
8 mg/week (the maximum dose authorized for adults in
Japan) in 26 (38.2%) of the 68 cases. The MTX dosing
period was 3 months at a minimum, 20 years and 7 months
at a maximum, with a median of 8 years, and an average of
5.11 ± 4.12 years. Adverse events were noted in 10 cases
(14.7%), including four with nausea/vomiting and one each
with diarrhea, headache, malaise, varicella complication,
aggravation of arthritis and duodenal ulcers (a causal rela-
tionship of the last event to the drug was noted by the
attending physician to be unlikely since the symptoms
worsenedafterincreasingtheNSAIDdose).Oftheseevents,
all but duodenal ulcers were non-severe, and all subsided
rapidly. The frequency of dosing per week was once in 18
cases and twice in 50 cases, with a mean of 1.74 ± 0.44. No
case received the drug in three or more divided doses.
Acquisition for approval to expand indications
At the Pediatric Drug Therapy Conference organized under
the Ministry of Health, Labour and Welfare, there have
been discussions regarding expansion of the indications for
MTX to include JIA accompanied by articular symptoms,
on the basis of the information presented above, including
the status of approval in four Western countries with
similar drug approval systems (USA, UK, Germany and
France), the overseas literature (randomized comparisons,
pharmacokinetic studies), published reports (reviews,
meta-analyses, etc. published in peer-reviewed journals),
references in textbooks or the like to MTX as a standard
therapy, and domestic MTX use survey data.
Overall evaluation of efﬁcacy
The Cochran Assessment states that: ‘‘Little evidence has
been collected for efﬁcacy of MTX in treatment of JIA.
The evidence currently available is mostly based on non-
controlled clinical studies. Although the data from con-
trolled studies reportedly endorsed signiﬁcant alleviation of
clinical symptoms, there are open questions on its efﬁ-
cacy.’’ However, as stated above, MTX is referred to in
many of the representative domestic and overseas text-
books, review papers published in leading journals,
guidelines and so on. The response rate to MTX was 70%–
90% in many reports. In randomized controlled studies,
MTX was shown to be more effective than a placebo and to
induce radiological improvements. In the USA and
Germany, the indications for MTX are ‘‘polyarticular JIA’’.
Some textbooks also refer to the efﬁcacy of MTX in the
treatment of polyarticular JIA. Some reports, however,
show that this drug is also effective against the systemic
type or the less-joint affecting type of this disease. In
France, the indications for this drug are not conﬁned to
multiple-joint type disease. In the UK, approval of MTX
preparation has not been issued directly, but the guidelines
for etanercept using biological preparations (the most
powerful means of treatment currently available) state that
these preparations are used in cases failing to respond to
MTX, without limiting the subjects of MTX treatment to
those with multiple-type joint disease. In the Japanese
guidelines as well, there is a statement that the drug is used
even in systemic type cases if arthritis symptoms constitute
the only major abnormalities. We therefore judged it to be
appropriate to set the indications for MTX in Japan as ‘‘JIA
accompanied by articular symptoms.’’
We may say that there is adequate evidence supporting
approval of this drug as a means of treating this disease in
Japan.
Global assessment of safety
According to the PK data available on children of the
corresponding ages, the Cmax of MTX following oral
administration was 0.4–1.0 lM/L, higher than the known
toxic range of MTX (over 0.1 lM/L). However, Tmax was
achieved in 1–2 h, and T1/2 was 1–2 h. Thus, the blood
MTX level rapidly dropped below the toxic range. There
are also reports on the results of controlled studies (double-
blind, etc.) and other major studies as well as reports on
adverse reactions and case reports. Deﬁnite evidence for
the safety for this drug is thus available. When using MTX,
care is needed of delayed absorption and increased Cmax,
AUC, etc. following the use of MTX in combination with
NSAIDs, since reports on such changes are available. This
point is already noted in the package insert for MTX in
Japan.
Adverse reactions to MTX used for JIA treatment are
summarized in the aforementioned Nelson Textbook of
Pediatrics (17th edition, 2004) [36]. MTX is well tolerated
by children and the dose needed is low. Therefore, adverse
reactions to MTX used for JIA treatment are minimal as
compared to those known for its use in cancer treatment.
The adverse reactions also differ qualitatively when this
drug is used for JIA. Regarding the known hepatotoxicity
of MTX in adults with RA, minute attention should be paid
when MTX is used for children. However, liver biopsy in
JIA children receiving long-term MTX therapy revealed no
abnormalities in most cases. When used for adults, lym-
phoproliferative disorders developing after initial EB virus
infection have been reported. A direct association of MTX
with this event can not be ruled out.
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Capsule (2 mg) used for treatment of adult RA (published
on December 26, 2006) [37] include the following data.
Among 3,839 cases included in the safety evaluation, the
incidence of adverse reactions was 18.62%. When the
incidence of adverse reactions was analyzed by system
organ class, it was highest for hepatobiliary (5.37%, 206
cases), followed by gastrointestinal (4.74%, 182 cases) and
general (2.27%, 87 cases) disorders. The incidence of
adverse reactions likely to follow severe courses was
1.48% (57 cases) for respiratory disorders and 1.38% (53
cases) for white blood cell and reticuloendothelial system
disorders. As compared to the incidences of adverse reac-
tions described in the Nelson Textbook of Pediatrics, those
in this survey were lower for gastrointestinal and hepatic
disorders. This difference seems to be attributable to the
mean MTX dose for patients in whom data on doses were
available being below 6 mg/week (in divided doses) in
97.77% of all cases (1,712/1,751), resulting in a much
lower dose per unit body surface area as compared to that
for children. Regarding adverse reactions likely to follow
severe courses (i.e., leucopenia and interstitial pneumonia),
incidences were lower in children described in the Nelson
Textbook of Pediatrics than in this domestic survey of adult
RA cases.
In this clinical use survey, adverse events were noted in
ten cases (1.47%), including four with nausea/vomiting and
one case each of diarrhea, headache, malaise, varicella
complication, aggravation of arthritis and duodenal ulcers
(a causal relationship of the last event to the drug was noted
by the attending physician to be unlikely since the symp-
toms worsened after the NSAID dose was increased). Of
these events, all but duodenal ulcers were non-severe, and
all subsided rapidly, allowing a judgment that none had
given rise to signiﬁcant safety problems.
If these survey data and the adverse reaction ﬁndings
described in package inserts, literature, textbooks, etc. are
combined for general evaluation, there is no noteworthy
difference in the safety proﬁles of this drug between Japan
and foreign countries, and we can thus judge that there are
no safety problems which could serve as obstacles to the
approval of this drug for pediatric use in Japan.
Validity of dosage and administration
Regarding the use of this drug for children in Western
countries, the initial dose is usually 10 mg/m
2 per week
and the maximum 20 or 30 mg/m
2 per week, as stated
above. The dosing method and dosage in Japan have
already described in ‘‘Overseas published information,
randomized comparative studies and reports on pharma-
cokinetics’’. That is, in Japan, the drug is often used at an
initial dose between 4 and 10 mg/m
2 per week, identical to
the routine initial dose in Western countries. MTX is
known to exert its efﬁcacy dose-dependently. Adverse
reactions appearing in a dose-dependent manner (hepatic
dysfunction, mucosal disorders, bone marrow suppression,
etc.) are known, and the MTX excretion rate differs
depending on the growth stages of individual children.
With these and other issues taken into account, it seems
advisable to present a range of initial doses (between 4 and
10 mg/m
2 per week) so that physicians can adjust the ini-
tial dose based on the features of individual children
receiving this drug in Japan. Although no factor allowing
clear-cut determination of the maximum dose of this drug
is known, it seems essential to bear in mind that the
maximum dose in said clinical use survey was 17 mg/m
2
per week, and that the safety of this drug at doses over
20 mg/m
2 per week has not been adequately assessed in the
USA.
Regarding the dosing method, once weekly administra-
tion is usually adopted for MTX therapy in foreign
countries. However, it seems appropriate to set the dosing
method at once weekly or 2–3 divided doses per week in
view of the following factors: (1) in the domestic clinical
use survey, divided doses (two doses/week) were some-
times adopted; (2) self-control is difﬁcult for children,
unlike adult patients, thus making it necessary to consider
adoption of a once weekly regimen to improve compliance
with dosing instructions; and (3) the drug is administered in
three divided doses/week when used for the treatment of
adult RA in Japan.
According to the current dosing method and dose of
MTX for adult RA in Japan, the drug is administered by
dividing the weekly dose (6 mg) into three, at intervals of
12 h, with an upper weekly dose limit of 8 mg. In Western
countries, the drug is usually used at an initial dose of
7.5 mg/week and at a maximum dose of 20 mg/week.
According to the results of re-examination of the Rheu-
matrex
  Capsule (2 mg) used for the treatment of adult
RA, the dose was below 6 mg/week in 98% of all cases.
However, according to the interim analysis of the data from
the thorough survey on etanercept (June 2007), the MTX
dose for combined therapy was over 8 mg/week in 38.8%
and over 10 mg/week in 5.7% of all cases [38]. According
to the survey conducted by the Japan Rheumatism Foun-
dation (2000) as well, 39.8% of physicians pointed out the
necessity of an MTX dose exceeding 8 mg/week [39].
Under such circumstances, the enterprise manufacturing
and distributing this drug is reviewing the dosing method
and dose of this drug for adults. Therefore, although the
dosing method and dose now proposed for pediatric use are
not completely consistent with the current dosing method
and dose for adults, we judge this proposal to be optimal at
present, provided that the proposed dosing method and
dose are reviewed appropriately in the future on the basis
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considering a report that tolerability for this drug was lower
in adults than children, particular care is needed in deter-
mining the dose for preadolescent and older children with
juvenile idiopathic arthritis.
Based on these discussions, expansion of the indications
for MTX to include JIA was judged to be acceptable, and it
was approved at the Pediatric Drug Therapy Conference of
the Ministry of Health, Labour and Welfare and at the
Pharmaceutical and Food Council.
Revised package insert
• Drug concerned: Rheumatrex
  Capsule (2 mg) and all
drugs of equivalent efﬁcacy.
• Planned indications: juvenile idiopathic arthritis
accompanied by articular symptoms.
• Planned administration and dosage: usually, the drug is
orally administered at a dose of 4–10 mg/m
2 per week
(on a methotrexate basis). The dose is adjusted
accordingly depending on age, symptoms, tolerability,
responses, etc.
The drug is orally administered once weekly or by dividing
the weekly dose into two or three. If the drug is adminis-
tered in two or three divided doses, it should be
administered at intervals of 12 h on two consecutive days.
Cessation is incorporated for the remaining 6 days of the
week in case of once weekly treatment or two divided
treatments, and for the remaining 5 days in case of three
divided treatments. This treatment sequence is repeated for
multiple weeks.
Precautions related to administration and dosage: When
using this drug, adequate care is needed as to the appear-
ance of adverse reactions, and the dose should be set at an
appropriate level for each patient depending on individual
circumstances, including assessment of tolerability and
responses. Considering a report that the tolerability of this
drug was lower in adults than children, particular care is
needed in determining the dose for preadolescent and older
children with juvenile idiopathic arthritis.
Conclusions
At the present conference, expansion of the indications for
MTX in JIA was approved. It is noteworthy that this
expansion of indications was achieved without requiring
clinical trials on children sponsored by the pharmaceutical
company, by collecting necessary information through
ongoing efforts (including collection and analysis of
information about approval status in foreign countries,
adequate evidence from the literature, implementation of a
clinical use survey in Japan, and so on). It also merits
attention that the maximum dose (10 mg/m
2) was set on
the basis of pharmacokinetic data from children, rather
than relying on the dosing method and dose for adults.
As to other drugs which can be used in the management
of pediatric rheumatism, it is desirable that efforts should
be made henceforth on to expand or acquire indications for
these drugs, through adequate analysis of the characteris-
tics of pediatric patients, collection of adequate evidence
from the literature and implementation of clinical use
surveys.
Acknowledgments The authors thank Pediatric Rheumatology
Association of Japan and Japan Society of Developmental Pharma-
cology and Therapeutics to expand the indications for MTX in JIA in
Japan. In addition, we deeply thank all the attendants who gave
precious comments in MTX working group or the study group on
pediatric drug therapy in Ministry of Health, Labour and Welfare. The
Japanese version of this work was published as the report from the
subcommittee for juvenile idiopathic arthritis in the Japan Pediatric
Society. We are grateful to Mr. C. W. P. Reynolds for his careful
linguistic assistance with this manuscript.
Conﬂict of interest statement We declare that no ﬁnancial conﬂict
of interest exists with any commercial entity whose products are
described, reviewed, evaluated or compared in the manuscript.
References
1. Harrington J. Developmental issues in adolescence and the
impact of rheumatic disease. In: Isenberg DA, Miller JJ, editors.
Adolescent rheumatology. London: Martin Dunitz; 2000. p. 21–
34.
2. Petty RE, Cassidy JT. Chronic arthritis, poly arthritis, oligoar-
thritis, systemic arthritis. In: Cassidy JT, Petty RE, Laxer RM,
Linsley CB, editors. Textbook of pediatric rheumatology. 5th ed.
Philadelphia: Elsevier Saunders; 2005. p. 206–303.
3. Fujikawa S, Okuni M. A nationwide surveillance study of rheu-
matic diseases among Japanese children. Acta Paediatr Jpn.
1997;39:242–4.
4. Yokota S. Investigation of the actual situation and medical
administrative policy for QOL improvement in patients with
juvenile rheumatoid arthritis. Public Welfare Labor Science
Study, 2000.
5. Hollingworth P. The use of non-steroidal anti-inﬂammatory drugs
in paediatric rheumatic diseases. Br J Rheumatol. 1993;32:73–7.
6. Cassidy JT. Outcomes research in the therapeutic use of metho-
trexate in children with chronic peripheral arthritis. J Pediatr.
1998;133:179–80.
7. Ramanan AV, Whitworth P, Baildam EM. Use of methotrexate in
juvenile idiopathic arthritis. Arch Dis Child. 2003;88:197–200.
8. Yokota S. Classiﬁcation and treatment strategy for juvenile idi-
opathic arthritis. Therapy. 1999;81:766–72.
9. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A,
Vorontsov I, et al. Methotrexate in resistant juvenile rheumatoid
arthritis. Results of the USA-USSR. double-blind, placebo-con-
trolled trial. The Pediatric Rheumatology Collaborative Study
Group and The Cooperative Children’s Study Group. N Engl J
Med 1992; 326: 1043–9.
10 Mod Rheumatol (2009) 19:1–11
12310. Woo P, Southwood TR, Prieur AM, Dore CJ, Grainger J, David J,
et al. Randomized, placebo-controlled, crossover trial of low-
dose oral methotrexate in children with extended oligoarticular or
systemic arthritis. Arthritis Rheum. 2000;43:1849–57.
11. National Institute for Clinical Excellence March 2002. Technol-
ogy Appraisal No. 35. Guidance on the use of etanercept for the
treatment of juvenile idiopathic arthritis. http://www.nice.org.uk/.
12. Past package inserts for Rheumatrex
  Capsule 2 mg. Revised
February 2007.
13. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D,
Macfarlane JD, et al. Therapeutic efﬁcacy of multiple intravenous
infusions of anti-tumor necrosis factor alpha monoclonal
antibody combined with low-dose weekly methotrexate in rheu-
matoid arthritis. Arthritis Rheum. 1998;41:1552–63.
14. Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6
receptor antibody treatment in rheumatic diseases. Ann Rheum
Dis. 2000;59(Suppl 1):21–27.
15. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED,
Nocton JJ, et al. Etanercept in children with polyarticular juvenile
rheumatoid arthritis. Pediatric Rheumatology Collaborative
Study Group. N Engl J Med. 2000;342:763–9.
16. Brewer EJ Jr, Giannini EH. Standard methodology for Segment I,
II, and III Pediatric Rheumatology Collaborative Study Group
studies. I. Design. J Rheumatol. 1982;9:109–13.
17. Silverman E, Mouy R, Spiegel L, Jung LK, Saurenmann RK,
Lahdenne P, et al. Leﬂunomide or methotrexate for juvenile
rheumatoid arthritis. N Engl J Med. 2005;352:1655–66.
18. Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK,
Falcini F, et al. A randomized trial of parenteral methotrexate
comparing an intermediate dose with a higher dose in children
with juvenile idiopathic arthritis who failed to respond to stan-
dard doses of methotrexate. Arthritis Rheum. 2004;50:2191–201.
19. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT,
Martini A. Preliminary deﬁnition of improvement in juvenile
arthritis. Arthritis Rheum. 1997;40:1202–9.
20. Ruperto N, Ravelli A, Falcini F, Lepore L, De Sanctis R, Zulian
F, et al. Performance of the preliminary deﬁnition of improve-
ment in juvenile chronic arthritis patients treated with
methotrexate. Italian Pediatric Rheumatology Study Group. Ann
Rheum Dis. 1998;57:38–41.
21. Hunt PG, Rose CD, McIlvain-Simpson G, Tejani S. The effects
of daily intake of folic acid on the efﬁcacy of methotrexate
therapy in children with juvenile rheumatoid arthritis. A con-
trolled study. J Rheumatol. 1997;24:2230–2.
22. Balis FM, Savitch JL, Bleyer WA. Pharmacokinetics of oral
methotrexate in children. Cancer Res. 1983;43:2342–5.
23. Ravelli A, Di Fuccia G, Molinaro M, Ramenghi B, Zonta L,
Regazzi MB, et al. Plasma levels after oral methotrexate in
children with juvenile rheumatoid arthritis. J Rheumatol. 1993;
20:1573–7.
24. Albertioni F, Flato B, Seideman P, Beck O, Vinje O, Peterson C,
et al. Methotrexate in juvenile rheumatoid arthritis. Evidence of
age dependent pharmacokinetics. Eur J Clin Pharmacol. 1995;
47:507–11.
25. Dupuis LL, Koren G, Shore A, Silverman ED, Laxer RM.
Methotrexate-nonsteroidal antiinﬂammatory drug interaction in
children with arthritis. J Rheumatol. 1990;17:1469–73.
26. Pinkerton CR, Welshman SG, Glasgow JF, Bridges JM. Can food
inﬂuence the absorption of methotrexate in children with acute
lymphoblastic leukaemia? Lancet. 1980;2:944–6.
27. Dupuis LL, Koren G, Silverman ED, Laxer RM. Inﬂuence of
food on the bioavailability of oral methotrexate in children.
J Rheumatol. 1995;22:1570–3.
28. Bannwarth B, Pehourcq F, Lequen L. Pharmacokinetics of
methotrexate in rheumatoid arthritis: therapeutic implications.
Therapie. 1997;52:129–32.
29. Wallace CA, Bleyer WA, Sherry DD, Salmonson KL,
Wedgwood RJ. Toxicity and serum levels of methotrexate in
children with juvenile rheumatoid arthritis. Arthritis Rheum.
1989;32:677–81.
30. Kasapcopur O,Cullu F, Kamburoglu-Goksel A,Cam H, Akdenizli
E, Calykan S, et al. Hepatitis B vaccination in children with
juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63:1128–30.
31. Takken T, Van Der Net J, Helders PJ. Methotrexate for treating
juvenile idiopathic arthritis. Cochrane Database Syst Rev 2001:
CD003129.
32. Giannini EH, Cassidy JT, Brewer EJ, Shaikov A, Maximov A,
Kuzmina N. Comparative efﬁcacy and safety of advanced drug
therapy in children with juvenile rheumatoid arthritis. Semin
Arthritis Rheum. 1993;23:34–46.
33. Ravelli A, Martini A. Methotrexate in juvenile idiopathic
arthritis: answers and questions. J Rheumatol. 2000;27:1830–3.
34. Yokota S. Recent topics on rheumatism and collagen diseases in
childhood. Nippon Naika Gakkai Zasshi 2007; 96: 2226–34 (in
Japanese).
35. Aihara Y, et al. The MTX therapy for juvenile idiopathic arthritis.
Ryumach 40: 336, 2000 (Proceedings of the 44th meeting of the
Japan College of Rheumatology) (in Japanese).
36. Nelson Textbook of Pediatrics (17th editon, 2004) Chapter 114
http://www.mdconsult.com/das/book/0/view/1175/instruct.html.
37. Proper use information for Rheumatrex
  Capsule 2 mg (vol 12):
Reexamination application material (Use Result Surveillance and
Special Use-Result Surveillance), prepared in January 2007.
38. Proper use information for Enbrel
  Subcutaneous injection
25 mg (vol 6): all cases surveillance interim report II (n = 7,091
cases), prepared in June 2007.
39. Kawai S, Ochi T, Kondo H, Nishioka K, Nobuyuki N, Yoshino S.
A survey of the doses of methotrexate and salazosulfapyridine in
Japanese patients with rheumatoid arthritis. Ryumachi 2002; 42:
76–9 (in Japanese).
Mod Rheumatol (2009) 19:1–11 11
123